Optimal anticoagulation prior to cath: Bivalirudin vs. Heparin the saga continues…

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Non-ST elevation myocardial infarction (Non-STEMI) management involves a critical pre-procedural medication phase.
• Early invasive strategies are standard for Non-STEMI, necessitating careful consideration of antithrombotic therapy.
• Optimizing peri-procedural care is crucial to mitigate ischemic and bleeding risks.

Discussion:

• Bivalirudin monotherapy demonstrated the lowest bleeding rates compared to other anticoagulants in the pre-procedural phase for Non-STEMI patients.
• Unfractionated heparin (UFH) monotherapy showed comparable safety and efficacy to bivalirudin, suggesting interchangeability.
• Upstream use of Glycoprotein inhibitors (GPI) in conjunction with anticoagulants should be avoided due to increased bleeding and net adverse events.

Key Insights:

• Bivalirudin monotherapy is the preferred anticoagulant to minimize bleeding in Non-STEMI patients undergoing early invasive procedures.
• Concurrent use of upstream GPIs with anticoagulants (bivalirudin or UFH) is associated with higher bleeding risks and should be discouraged.
• A multi-faceted strategy involving low-dose aspirin, potent P2Y12 inhibitors, and a transradial approach with drug-eluting stents may reduce perioperative complications.

Outlook:

• Further research could explore optimal P2Y12 inhibitor selection and dosing in this patient cohort.
• Investigating the long-term outcomes of the combined strategy (aspirin, P2Y12 inhibitors, transradial approach, DES) is warranted.
• Comparative studies evaluating different antithrombotic regimens in specific Non-STEMI subgroups may refine clinical practice.